| Previous Close | 0.0725 |
| Open | 0.0777 |
| Bid | 0.000 x 0 |
| Ask | 0.000 x 0 |
| Day's Range | 0.0700 - 0.0777 |
| 52 Week Range | 0.0450 - 0.2660 |
| Volume | 496,814 |
| Avg. Volume | 806,754 |
| Market Cap | 33.204M |
| Beta (3Y Monthly) | -0.24 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.016 |
| Earnings Date | Nov 13, 2018 - Nov 19, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
MIAMI, Feb. 12, 2019 -- Progressive Care Inc. (OTCQB: RXMD), a personalized healthcare services and technology company, today announced that CEO, Shital Mars will be the.
Progressive Care Inc. (OTCQB: RXMD), a personalized healthcare services and technology company, today announced that it has garnered media coverage in Insider Financial and Cannabis Radio Show as one of the top plays for investors looking to make money off the opioid crisis in the U.S. and using alternative medicine to combat the crisis. In an article titled Progressive Care Inc (RXMD): A Top Play on Opioid Crisis, published on January 14, 2019, Insider Financial discussed how Progressive Care is in an ongoing fight for non-opioid treatments for pain to be routinely covered by insurance.
Investorideas.com, a leading investor news resource covering technology and healthcare stocks releases a snapshot looking at how healthcare is changing in the digital age. Investorideas recently reported on how Digital Health technologies enabling out-of-hospital care and monitoring are forecast to grow by 30 percent and cross the $25 billion mark. In the article, Kamaljit Behera, Industry Analyst, Transformational Health, said, "In this highly digitized environment, artificial intelligence (AI) will permeate the life sciences ecosystem, and its use in healthcare IT (HIT) is likely to cross $1.7 billion by the end of 2019.
After reaching record revenues in 2017 of $20 million the Company moved forward on an agenda that would make us more resilient in the face of industry changes and push past our competitors in terms of service, expertise, and technology. Early in 2018, we planted the seeds of growth by filling record numbers of prescriptions and issuing an LOI for our first acquisition.
MIAMI, Jan. 16, 2019 -- Progressive Care Inc. (OTCQB: RXMD), a personalized healthcare services and technology company, today issued an update regarding the pharmacy.
MIAMI, Jan. 15, 2019 -- Progressive Care Inc. (OTCQB: RXMD), a personalized healthcare services and technology company, today announced further growth year-over-year in revenue.
Progressive Care Inc. (OTCQB: RXMD), a personalized healthcare services and technology company, today announced that it has entered into a new securities purchase agreement. Progressive Care has agreed to a secured promissory note providing $2.5 million in capital facility to the company, $1 million of which was funded on January 7, 2019 and $1.5 million will be available in tranches thereafter. The Company has secured this capital in advance of an ambitious 2019 agenda which includes logistical implementation of the company’s unique service offerings (DischargeRx, TelePharmacy, Full Service 340B Program), development of new product lines and digital technologies, expanded sales efforts of the core business, build-out of the recently acquired property, and acquisition support.
Progressive Care Inc. (OTCQB: RXMD), a personalized healthcare services and technology company, today announced that it has garnered media coverage in Authority Magazine as a hero of the opioid crisis. In an interview titled Heroes Of The Opioid Crisis, published December 27, 2018 in Authority Magazine Mars discusses how she would like to a see a bill that limits the extent to which a patient can be denied coverage for necessary medications. Today insurance companies are restricting benefits to the point where a patient can no longer get coverage for outpatient pain management solutions other than prescription grade ibuprofen, or Tylenol.
The Company issued a convertible promissory note (the “Note”) in the amount of $300,000 to the Seller to fund a portion of the price for such purchase. The Note bears interest at the rate of 10% per annum and is payable in full 27 months from the date of issuance. The outstanding principal and interest then payable under the Note is convertible into shares of the Company’s common stock 12 months after the date of issuance at the price per share equal to the average trading-price for the common stock during the three (3) trading day period ending on the latest complete trading day prior to the conversion date.
At the start of the interview Jolly mentioned the letter of intent issued by Progressive Care Inc. to purchase a Florida based pharmacy with 2 operating locations. “We want to grow organically but we also want to grow through acquisition,” explains Mars. Mars went on to explain the company they intend to purchase has a lot of synergies with who Progressive Care Inc. is as a company, including a pharmacy in Orlando which is a big market for the company.
Progressive Care Inc. (OTCQB: RXMD), a personalized healthcare services and technology company, today announced that it has garnered notable international media coverage in top pharmacy industry publication World Pharma Today stressing the importance of adherence and compliance in the space of medicine. In a contributed article titled “The Pharmacist Perspective: Medication Adherence & Compliance”, published November 26, 2018, in World Pharma Today, Mars focuses on adherence and its significance for patients who are prescribed medications.
Progressive Care Inc. (OTCQB: RXMD), a personalized healthcare services and technology company, today announced that it has entered into a letter of intent to purchase a Florida based pharmacy with 2 operating locations. On November 27, 2018, Progressive Care executed a letter of intent to purchase a Florida based pharmacy with locations in Davie and Orlando, Florida. The target pharmacy had just under $16 million in revenue in 2017 and is projected to have approximately $18 million for 2018.